Drug interaction study: bosentan may change zongertinib levels
NCT ID NCT07649941
First seen Jun 27, 2026 · Last updated Jul 28, 2026 · Updated 3 times
Summary
This early-stage trial will test whether taking bosentan (a drug for blood pressure) changes how the body processes zongertinib (an experimental cancer drug). Sixteen healthy men will receive zongertinib alone and then with bosentan to compare drug levels. The study is not intended to treat any disease, but to gather safety and dosing information for future research.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- bosentan and zongertinib
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Humanpharmakologisches Zentrum Biberach
Biberach, 88397, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test